- Revenue grows despite challenges in key markets
- R&D spend increases for gene-edited pigs
Performance at animal genetics group Genus (GNS) has been hamstrung in recent quarters by volatility in the price of live pigs in China. But some signs of a sustained recovery were evident in the six months to 31 December, with revenue for the group’s porcine products division (known as PIC) increasing by 12 per cent.